- Email: [email protected]
PD25. Progress in targeted therapies for head and neck cancer
Pan. Disc. & Symp. Abs.Keynote Abs.Keynote Bios.ProgramIAOOWelcomeCommittee Listings Poster Abstracts Oral AbstractsPoster List
16
Panel discussions and symposia abstracts / Oral Oncology Supplement 3 (2009) 11–23
Purpose: To understand the properties and potential benefits of platelet concentrates on wound healing, and to evaluate the clinical applications of autologous platelet adhesives in soft-tissue surgery of the head and neck. Platelets play an important role in wound healing through activation which releases growth factors and cytokines, and by initiating the clotting cascade. With advances in autologous platelet harvesting technology, high concentrations of platelets or fibrin autologous tissue adhesives can be obtained from the patients’ own blood for immediate application at the time of surgery. The potential benefits to wound healing afforded by supraphysiologic concentration of platelets may thus be exploited. Despite their intuitive appeal, broad applications in soft tissue surgery have been limited. Recent clinical investigations have demonstrated early promise in improved wound healing, graft survival, and delayed fibrosis. We will present our experience with the use of platelet concentrates in the head and neck population. doi:10.1016/j.oos.2009.06.036
PD24. Tissue Engineering C. Cloakie University of Toronto, Canada [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.037
Panel discussion 7: Progress in targeted therapies PD25. Progress in targeted therapies for head and neck cancer C. Nutting Royal Marsden Hospital, UK Targeted therapy has now emerged as an effective treatment strategy in head and neck cancer, and has become widely used outside the constraints of clinical trials. The randomised trials of inhibition of the epidermal growth factor receptor (EGFRI) with Cituximab will be presented and discussed, both in the context of radical radiotherapy, as well as its combination with palliative chemotherapy schedules. More recently data on targeting of additional important biological targets has become available. These tyrosine kinase inhibitors (e.g. Lapatinib) target multiple growth factor receptor pathways and are currently under intensive investigation. The implementation of these new treatment modalities in the clinic has required development of new strategies to manage the toxicities of these new therapies, and these will be presented.
ditions. In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive mechanisms and enables a measurable antitumor immune response to be generated that substantially delays tumor progression. In particular, sildenafil, downregulates arginase 1 and nitric oxide synthase-2 expression, thereby reducing the suppressive machinery of CD11b+/Gr-1+ myeloidderived suppressor cells (MDSCs) recruited by growing tumors. By removing these tumor escape mechanisms, sildenafil enhances intratumoral T-cell infiltration and activation, and reduces tumor outgrowth, and improves the antitumor efficacy of adoptive T-cell therapy. Sildenafil also restores in vitro T-cell proliferation of peripheral blood mononuclear cells from multiple myeloma and head and neck cancer patients. These findings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumor-specific immune therapy, and we have initiated a phase II trial to evaluate the efficacy of tadalafil in reversing T-cell immunosuppresion in patients with head and neck squamous cell carcinoma. doi:10.1016/j.oos.2009.06.039
PD27. TBC J. Bourhis Institut de cancérologie, France [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.040
PD28. TBC L. Licitra Fondazione Istituto Nazionale dei Tumori, Italy [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.041
Panel discussion 8: The disappearing ‘jaw’ PD29. Secondary augmentation fibula P. Cordeiro, Memorial Sloan-Kettering Cancer Center, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.042
doi:10.1016/j.oos.2009.06.038
PD26. Novel use of existing therapeutic agents for cancer therapy: Viagra and head and neck cancer J. Califano, I. Borrello Johns Hopkins Medical Institutions, USA Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents currently in clinical use for nonmalignant con-
PD30. Radionecrosis N. Futran University of Washington, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.043
16
Panel discussions and symposia abstracts / Oral Oncology Supplement 3 (2009) 11–23
Purpose: To understand the properties and potential benefits of platelet concentrates on wound healing, and to evaluate the clinical applications of autologous platelet adhesives in soft-tissue surgery of the head and neck. Platelets play an important role in wound healing through activation which releases growth factors and cytokines, and by initiating the clotting cascade. With advances in autologous platelet harvesting technology, high concentrations of platelets or fibrin autologous tissue adhesives can be obtained from the patients’ own blood for immediate application at the time of surgery. The potential benefits to wound healing afforded by supraphysiologic concentration of platelets may thus be exploited. Despite their intuitive appeal, broad applications in soft tissue surgery have been limited. Recent clinical investigations have demonstrated early promise in improved wound healing, graft survival, and delayed fibrosis. We will present our experience with the use of platelet concentrates in the head and neck population. doi:10.1016/j.oos.2009.06.036
PD24. Tissue Engineering C. Cloakie University of Toronto, Canada [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.037
Panel discussion 7: Progress in targeted therapies PD25. Progress in targeted therapies for head and neck cancer C. Nutting Royal Marsden Hospital, UK Targeted therapy has now emerged as an effective treatment strategy in head and neck cancer, and has become widely used outside the constraints of clinical trials. The randomised trials of inhibition of the epidermal growth factor receptor (EGFRI) with Cituximab will be presented and discussed, both in the context of radical radiotherapy, as well as its combination with palliative chemotherapy schedules. More recently data on targeting of additional important biological targets has become available. These tyrosine kinase inhibitors (e.g. Lapatinib) target multiple growth factor receptor pathways and are currently under intensive investigation. The implementation of these new treatment modalities in the clinic has required development of new strategies to manage the toxicities of these new therapies, and these will be presented.
ditions. In several mouse tumor models, PDE5 inhibition reverses tumor-induced immunosuppressive mechanisms and enables a measurable antitumor immune response to be generated that substantially delays tumor progression. In particular, sildenafil, downregulates arginase 1 and nitric oxide synthase-2 expression, thereby reducing the suppressive machinery of CD11b+/Gr-1+ myeloidderived suppressor cells (MDSCs) recruited by growing tumors. By removing these tumor escape mechanisms, sildenafil enhances intratumoral T-cell infiltration and activation, and reduces tumor outgrowth, and improves the antitumor efficacy of adoptive T-cell therapy. Sildenafil also restores in vitro T-cell proliferation of peripheral blood mononuclear cells from multiple myeloma and head and neck cancer patients. These findings demonstrate a potentially novel use of PDE5 inhibitors as adjuncts to tumor-specific immune therapy, and we have initiated a phase II trial to evaluate the efficacy of tadalafil in reversing T-cell immunosuppresion in patients with head and neck squamous cell carcinoma. doi:10.1016/j.oos.2009.06.039
PD27. TBC J. Bourhis Institut de cancérologie, France [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.040
PD28. TBC L. Licitra Fondazione Istituto Nazionale dei Tumori, Italy [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.041
Panel discussion 8: The disappearing ‘jaw’ PD29. Secondary augmentation fibula P. Cordeiro, Memorial Sloan-Kettering Cancer Center, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.042
doi:10.1016/j.oos.2009.06.038
PD26. Novel use of existing therapeutic agents for cancer therapy: Viagra and head and neck cancer J. Califano, I. Borrello Johns Hopkins Medical Institutions, USA Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadalafil, and vardenafil) are agents currently in clinical use for nonmalignant con-
PD30. Radionecrosis N. Futran University of Washington, USA [Abstract not available at time of print.] doi:10.1016/j.oos.2009.06.043